Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Griet Compernolle

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Inflammatory Bowel Diseases|October 25, 2019
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral CenterMichiel Bronswijk, Annick Moens, Matthias Lenfant, et al.
Inflammatory Bowel Diseases|August 11, 2019
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral CenterMichiel Bronswijk, Annick Moens, Matthias Lenfant, et al.
Journal of Crohn'S & Colitis|March 2, 2019
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre StudyNiels Vande Casteele, Filip Baert, Sumin Bian, et al.
Inflammatory Bowel Diseases|November 16, 2017
Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over TimeSumin Bian, Erwin Dreesen, Ho Tsun Tang, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 3, 2020
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasisNathalie Van den Berghe, Aurélie Truffot, Miet Peeters, et al.
Gastroenterology|March 1, 2015
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel diseaseNiels Vande Casteele, Marc Ferrante, Gert Van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2018
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Bram Verstockt, Sumin Bian, et al.
Therapeutic Drug Monitoring|June 7, 2014
Development of a universal anti-adalimumab antibody standard for interlaboratory harmonizationAnn Gils, Niels Vande Casteele, Raf Poppe, et al.
United European Gastroenterology Journal|July 19, 2019
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel diseaseJurij Hanžel, Nejc Sever, Ivan Ferkolj, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 23, 2016
Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assaysSumin Bian, Thomas Van Stappen, Filip Baert, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Inflammatory Bowel Diseases|October 25, 2019
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral CenterMichiel Bronswijk, Annick Moens, Matthias Lenfant, et al.
Inflammatory Bowel Diseases|August 11, 2019
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral CenterMichiel Bronswijk, Annick Moens, Matthias Lenfant, et al.
Journal of Crohn'S & Colitis|March 2, 2019
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre StudyNiels Vande Casteele, Filip Baert, Sumin Bian, et al.
Inflammatory Bowel Diseases|November 16, 2017
Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over TimeSumin Bian, Erwin Dreesen, Ho Tsun Tang, et al.
Journal of Pharmaceutical and Biomedical Analysis|July 3, 2020
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasisNathalie Van den Berghe, Aurélie Truffot, Miet Peeters, et al.
Gastroenterology|March 1, 2015
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel diseaseNiels Vande Casteele, Marc Ferrante, Gert Van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2018
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Bram Verstockt, Sumin Bian, et al.
Therapeutic Drug Monitoring|June 7, 2014
Development of a universal anti-adalimumab antibody standard for interlaboratory harmonizationAnn Gils, Niels Vande Casteele, Raf Poppe, et al.
United European Gastroenterology Journal|July 19, 2019
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel diseaseJurij Hanžel, Nejc Sever, Ivan Ferkolj, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 23, 2016
Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assaysSumin Bian, Thomas Van Stappen, Filip Baert, et al.
Pageof 3